Cost Management Insights: SG&A Expenses for Novartis AG and Sarepta Therapeutics, Inc.

Navigating SG&A Expenses: Novartis AG vs. Sarepta Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry players: Novartis AG and Sarepta Therapeutics, Inc., from 2014 to 2023.

Novartis AG: A Steady Course

Novartis AG, a global healthcare leader, has maintained a relatively stable SG&A expense pattern over the years. Despite a slight dip in 2023, their expenses hovered around $14 billion annually, reflecting a strategic balance between operational efficiency and market expansion.

Sarepta Therapeutics, Inc.: A Growth Trajectory

In contrast, Sarepta Therapeutics, Inc., a pioneer in precision genetic medicine, has seen a remarkable increase in SG&A expenses, growing nearly tenfold from 2014 to 2023. This surge underscores their aggressive investment in research and market penetration.

This comparative insight highlights the diverse strategies employed by pharmaceutical giants in managing operational costs.